Big Board

Keyword
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 New Xarelto (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
2 New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
3 PBS listing of Taltz and Xarelto
4 Rivaroxaban noninferior to warfarin in patients with AF, bioprosthetic mitral valve: RIVER
5 Rivaroxaban may be as effective as warfarin for bioprosthetic mitral valves, AF
6 Xarelto: Side effects, dosage, uses, and more
7 EMA's CHMP gives Gamifant a second thumbs down; approves five new medicines
8 Post-COVID Heart Syndrome; Auto-Antibodies in COVID Clotting; CT Training
9 Bayer takes multiple hits in tough third quarter
10 Janssen Submits Application to US FDA for New Indication to Expand Use of XARELTO® (rivaroxaban) in Patients with Peripheral Artery Disease
11 ACC: J&J, Bayer's blood thinner Xarelto scores in artery disease post-surgery
12 Visalia Medical Clinic clinic helps patients find the right balance
13 Investors Wish They Could Vote These 2 Healthcare CEOs Out
14 Global Anticoagulants (Xarelto, Eliquis, Pradaxa and Savaysa) Market to 2024 Featuring Key Players
15 ESC: Pfizer, BMS' Eliquis tops Xarelto, vitamin K drugs for site-specific bleeding risks in French real-world study
16 Does Medicare Cover Xarelto?
17 Scanning the horizon for future Covid-19 treatments
18 Eliquis vs Xarelto: Which Is Better in Afib?
19 San Antonio research center begins COVID-19 patient trial for anticoagulant drug Xarelto
20 Landmark Phase 3 VOYAGER PAD Study of XARELTO® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
21 June 22 coronavirus news
22 Medicare and Xarelto: Coverage, generic options, and costs
23 Bayer
24 Bayer dials up Roundup settlement price—and takes a $11B write-down—as pharma fails to pick up slack
25 Major Bleed Risk Higher With Warfarin Than Xarelto in CTEPH...
26 Anticoagulants Market– Upcoming Opportunities by 2025 – Daily Research Correspondent
27 US FDA Approves XARELTO® (rivaroxaban) to Help Prevent Blood Clots in Acutely Ill Medical Patients
28 XARELTO® (rivaroxaban) Reduces Recurrent Blood Clots and Total Medical Costs in Morbidly Obese Patients
29 Rivaroxaban May Yet Protect After a Hospital Stay: MARINER
30 Xarelto Slashes VTE After Nonmajor Orthopedic Surgery
31 U.S. FDA Approves Xarelto (Rivaroxaban) to Help Prevent Blood Clots in Acutely Ill Medical Patients
32 Rivaroxaban sNDA Submitted for Symptomatic Peripheral Artery Disease
33 Bayer and Johnson & Johnson Settle Lawsuits Over Xarelto, a Blood Thinner, for $775 Million
34 Is Common Blood Thinner Safe? What to Know After Lawsuit
35 Study Bolsters Case for Novel Xarelto Formulation for Kids
36 J&J, Bayer's Xarelto scores FDA nod to treat acutely ill patients during and after hospitalization
37 Xarelto (Rivaroxaban) Reduces Recurrent Blood Clots and Total Medical Costs in Morbidly Obese Patients
38 Phase 3 trials: XARELTO vascular dose plus aspirin in treating patients with atherosclerotic disease
39 Rivaroxaban associated with reduced risk of recurrent VTE versus warfarin in patients with obesity
40 First EMA Nod For Generic Xarelto; Apotex Pulls Upkanz For Neurodegenerative Disease
41 AHA: Johnson & Johnson, Bayer still looking for answers in aborted Xarelto study
42 XARELTO® (rivaroxaban) Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study
43 FDA Approves New 10 mg Dosing for XARELTO® (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
44 Xarelto | Uses, Dosing & Interactions With the Blood Thinner
45 Sellers of blood-thinner drug to settle about 25,000 suits for $775M
46 US FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
47 Eliquis: Side effects, dosage, uses, generic, and more
48 New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli Compared to Warfarin in Frail Patients with Non-Valvular Atrial Fibrillation
49 Finding resilience after recurring events (Sponsored)
50 Low-Dose Xarelto Beats Aspirin for Long-Term Prevention of Life-Threatening Blood Clots
51 Key PBS listing to save Australians with severe back and neck pain more than $20000
52 Bayer and Janssen pay $775m to settle Xarelto misinformation claims
53 Could Extended Anticoagulation Help After COVID-19?
54 Which Blood Thinner Is Right for You?
55 Xarelto falls into the donut hole
56 Xarelto Harm for TAVR Patients Still Unexplained
57 Competition and donut hole discount takes toll on Xarelto sales
58 Xarelto Sees the Good, the Bad and the Potential for Ugly This Week
59 Xarelto Reversal Strategies And Bleeding Management
60 XARELTO® (rivaroxaban) Significantly Reduced the Risk of Overall Strokes and the Most Severe Strokes and Was Associated with Fewer Stroke-Related Deaths in the Real World Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation
61 Positive NICE recommendation for Xarelto to prevent atherothrombotic events in CAD and PAD patients
62 Xarelto Judge Taps Attorneys to Allocate $93M in Fees to Leading Firms | The Legal Intelligencer
63 Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgery | Small Molecules | News Channels
64 Post-Discharge Rivaroxaban Cuts Thromboembolic Events in Acutely Ill Patients
65 New Late-Breaking XARELTO® (rivaroxaban) and INVOKANA® (canagliflozin) Data to be Presented at the American College of Cardiology's Annual Scientific Session
66 Johnson & Johnson one-ups Eliquis as Xarelto nabs $1.5B FDA nod in artery disease
67 Updated Labeling for Rivaroxaban Related to Patients With Prosthetic Heart Valves
68 The cardiovascular scene to shift by 2024 as next-generation drugs like Eliquis and Xarelto eclipse stalwarts
69 New Phase 3 data advances pursuit of pediatric indication for Xarelto
70 Report: More than 15,000 Adverse Events Linked to Xarelto in 2016
71 Rivaroxaban Market To Find Better Growth with US$ 7.0 Billion By 2026 | CAGR: 1.5%: Coherent Market
72 NICE 'ok' for Bayer's Xarelto
73 Antidote For Xarelto's Extreme Bleeding May Be On The Horizon
74 Positive reimbursement decision for Xarelto in the UK
75 Caution When Prescribing Xarelto to First-Time Patients
76 Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
77 Bayer/J&J eye new paediatric use for anticoagulant Xarelto
78 Xarelto plaintiffs' lawyers win $114 million in fees, costs
79 Giving blood thinners to severely ill Covid-19 patients is gaining ground
80 DR. ROACH | Ask doctor about stopping Xarelto for procedure
81 Big trial failure for Xarelto in clot prevention won't affect sales, Bayer vows
82 J&J snaps up key label expansion for Xarelto
83 Xarelto no better than aspirin in secondary stroke study
84 Bayer selects Infor to solve asset pain
85 Despite a Q1 Drop in Sales, J&J Anticipates New Indications Will Increase Xarelto Revenue Growth
86 New Real-World Studies Showcase Significant Stroke Reduction with Xarelto (rivaroxaban)
87 Dr. Roach: If atrial fibrillation is on and off, why are meds full time?
88 Licensed indication for use of Xarelto in peripheral arterial disease
89 Johnson & Johnson targets different audiences with Xarelto TV commercial trio
90 NICE backs Bayer's Xarelto
91 ICER largely supportive of Xarelto and Vascepa as additive treatments for CD
92 J&J, Bayer accused of hiding Xarelto's dangers, face 18,000 patient lawsuits
93 J&J moving forward with US peds application for Xarelto, as Bayer preps European filing
94 FDA Approves Xarelto Bleeding Antidote in US
95 Bayer, J&J pull the plug on large Xarelto study
96 'Rivaroxaban 15mg useful NOAC without concern for renal function'
97 Xarelto Reduces Blood Clot Events in High-Risk Cancer Patients
98 How to Switch from Xarelto to Warfarin
99 New Analysis Shows People with Cancer Who Received XARELTO® (rivaroxaban) for Blood Clots Had Fewer ER Visits and Lower Healthcare Costs than Those Given Standard Treatment
100 First generics to Bristol-Myers and Pfizer's Eliquis are here. But can they launch before 2026?